GlaxoSmithKline PLC is projected to report Q2 2026 revenue of $10.79 billion and earnings per share of $1.27, with the stock currently trading at $51.39 against a consensus price target of $53.00.
Investors are primarily focused on the commercial momentum of the Vaccines division, specifically the blockbuster performance of the shingles vaccine Shingrix and the uptake of the RSV vaccine Arexvy.
This quarter serves as a critical milestone for new CEO Luke Miels as he executes the company's "pure biopharma" strategy following the successful spin-off of its consumer health business. Strong performance in Specialty Medicines, particularly in long-acting HIV regimens and a relaunched oncology portfolio, is expected to offset intensifying generic competition for legacy products.